The effect of multistage nanovector targeting of VEGFR2 positive tumor endothelia on cell adhesion and local payload accumulation

Biomaterials

Volumn 35, Issue 37, 2014, Pages 9824-9832

  Martinez, Jonathan O ^a,b   Evangelopoulos, Michael ^a   Karun, Vivek ^a   Shegog, Evan ^a   Wang, Joshua A ^a   Boada, Christian ^a,c   Liu, Xuewu ^a   Ferrari, Mauro ^a   Tasciotti, Ennio ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c ESCUELA DE MEDICINA Y CIENCIAS DE LA SALUD   (Mexico)

Author keywords

Drug delivery; Multi stage nanovectors; Nanoparticles; Tumor vascular targeting; Vascular endothelial growth factor receptor

Indexed keywords

ANTIBODIES; BIOCHEMISTRY; CELL ADHESION; CELL ENGINEERING; DRUG DELIVERY; ENDOTHELIAL CELLS; NANOPARTICLES;

ENHANCED ADHESIONS; ENHANCED PERMEABILITY AND RETENTION EFFECTS; NANOVECTORS; PARTICLE GEOMETRIES; REPORTER MOLECULES; SURFACE FUNCTIONALIZATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR; VASCULAR ENDOTHELIUM;

TUMORS;

MULTISTAGE NANOVECTOR; NANOCARRIER; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR ALPHA RECEPTOR 2; VASCULOTROPIN RECEPTOR 2; DRUG CARRIER; SILANE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOMIC EMISSION SPECTROMETRY; BIOACCUMULATION; BREAST TUMOR; CELL ADHESION; CELL POPULATION; CONJUGATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; FLUORESCENCE SPECTROSCOPY; IN VITRO STUDY; INFRARED RADIATION; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; SURFACE PROPERTY; TUMOR VASCULARIZATION; VASCULAR TUMOR; ANIMAL; BREAST NEOPLASMS; CELL LINE; CHEMISTRY; ENDOTHELIUM CELL; HUMAN; METABOLISM; NUDE MOUSE; PIG; VASCULARIZATION;

ANIMALS; BREAST NEOPLASMS; CELL ADHESION; CELL LINE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; FEMALE; HUMANS; MICE, NUDE; SILANES; SWINE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84907258415     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.08.024     Document Type: Article

References (57)

1. Azim H.A., de Azambuja E., Colozza M., Bines J., Piccart M.J. Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol 2011, 22:1939-1947.
2. Hansel T.T., Kropshofer H., Singer T., Mitchell J.A., George A.J. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010, 9:325-338.
3. Castanotto D., Rossi J.J. The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009, 457:426-433.
4. Song E., Zhu P., Lee S.K., Chowdhury D., Kussman S., Dykxhoorn D.M., et al. Antibody mediated in vivo delivery of small interfering rnas via cell-surface receptors. Nat Biotechnol 2005, 23:709-717.
5. Huang S., Shao K., Kuang Y., Liu Y., Li J., An S., et al. Tumor targeting and microenvironment-responsive nanoparticles for gene delivery. Biomaterials 2013, 34:5294-5302.
6. Kratz F., Warnecke A. Finding the optimal balance: challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systems. J Control Release 2012, 164:221-235.
7. Choi K.M., Jang M., Kim J.H., Ahn H.J. Tumor-specific delivery of siRNA using supramolecular assembly of hyaluronic acid nanoparticles and 2b RNA-binding protein/siRNA complexes. Biomaterials 2014, 35:7121-7132.
8. Olson E.S., Jiang T., Aguilera T.A., Nguyen Q.T., Ellies L.G., Scadeng M., et al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and mr imaging of proteases. Proc Natl Acad Sci U S A 2010, 107:4311-4316.
9. Raoof M., Cisneros B.T., Guven A., Phounsavath S., Corr S.J., Wilson L.J., et al. Remotely triggered cisplatin release from carbon nanocapsules by radiofrequency fields. Biomaterials 2013, 34:1862-1869.
10. Kwon I.K., Lee S.C., Han B., Park K. Analysis on the current status of targeted drug delivery to tumors. J Control Release 2012, 164:108-114.
11. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387-6392.
12. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
13. Terman B.I., Dougher-Vermazen M., Carrion M.E., Dimitrov D., Armellino D.C., Gospodarowicz D., et al. Identification of the kdr tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992, 187:1579-1586.
14. Millauer B., Wizigmann-Voos S., Schnurch H., Martinez R., Moller N.P., Risau W., et al. High affinity vegf binding and developmental expression suggest flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993, 72:835-846.
15. Potente M., Gerhardt H., Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011, 146:873-887.
16. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003, 9:653-660.
17. Crawford Y., Ferrara N. Vegf inhibition: insights from preclinical and clinical studies. Cell Tissue Res 2009, 335:261-269.
18. Ferrara N., Hillan K.J., Gerber H.-P., Novotny W. Discovery and development of bevacizumab, an anti-vegf antibody for treating cancer. Nat Rev Drug Discov 2004, 3:391-400.
19. Tasciotti E., Liu X., Bhavane R., Plant K., Leonard A.D., Price B.K., et al. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nano 2008, 3:151-157.
20. Lee S.Y., Ferrari M., Decuzzi P. Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows. Nanotechnology 2009, 20:495101.
21. Decuzzi P., Ferrari M. The adhesive strength of non-spherical particles mediated by specific interactions. Biomaterials 2006, 27:5307-5314.
22. Decuzzi P., Ferrari M. Design maps for nanoparticles targeting the diseased microvasculature. Biomaterials 2008, 29:377-384.
23. Adriani G., de Tullio M.D., Ferrari M., Hussain F., Pascazio G., Liu X., et al. The preferential targeting of the diseased microvasculature by disk-like particles. Biomaterials 2012, 33:5504-5513.
24. Serda R.E., Gu J., Bhavane R.C., Liu X., Chiappini C., Decuzzi P., et al. The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. Biomaterials 2009, 30:2440-2448.
25. van de Ven A.L., Kim P., Haley O., Fakhoury J.R., Adriani G., Schmulen J., et al. Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. J Control Release 2012, 158:148-155.
26. Decuzzi P., Godin B., Tanaka T., Lee S.Y., Chiappini C., Liu X., et al. Size and shape effects in the biodistribution of intravascularly injected particles. J Control Release 2010, 141:320-327.
27. Mann A.P., Tanaka T., Somasunderam A., Liu X., Gorenstein D.G., Ferrari M. E-selectin-targeted porous silicon particle for nanoparticle delivery to the bone marrow. Adv Mater 2011, 23:H278-H282.
28. Hou H., Nieto A., Ma F., Freeman W.R., Sailor M.J., Cheng L. Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon. J Control Release 2014, 178C:46-54.
29. Wu E.C., Park J.H., Park J., Segal E., Cunin F., Sailor M.J. Oxidation-triggered release of fluorescent molecules or drugs from mesoporous si microparticles. ACS Nano 2008, 2:2401-2409.
30. Salonen J., Laitinen L., Kaukonen A.M., Tuura J., Bjorkqvist M., Heikkila T., et al. Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs. J Control Release 2005, 108:362-374.
31. Martinez J.O., Brown B.S., Quattrocchi N., Evangelopoulos M., Ferrari M., Tasciotti E. Multifunctional to multistage delivery systems: the evolution of nanoparticles for biomedical applications. Chin Sci Bull 2012, 57:3961-3971.
32. Ananta J.S., Godin B., Sethi R., Moriggi L., Liu X., Serda R.E., et al. Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances t1 contrast. Nat Nanotechnol 2010, 5:815-821.
33. Zhang M., Xu R., Xia X., Yang Y., Gu J., Qin G., et al. Polycation-functionalized nanoporous silicon particles for gene silencing on breast cancer cells. Biomaterials 2014, 35:423-431.
34. Martinez J.O., Chiappini C., Ziemys A., Faust A.M., Kojic M., Liu X., et al. Engineering multi-stage nanovectors for controlled degradation and tunable release kinetics. Biomaterials 2013, 34:8469-8477.
35. Parodi A., Quattrocchi N., van de Ven A.L., Chiappini C., Evangelopoulos M., Martinez J.O., et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol 2013, 8:61-68.
36. De Rosa E., Chiappini C., Fan D., Liu X., Ferrari M., Tasciotti E. Agarose surface coating influences intracellular accumulation and enhances payload stability of a nano-delivery system. Pharm Res 2011, 28:1520-1530.
37. Fan D., De Rosa E., Murphy M.B., Peng Y., Smid C.A., Chiappini C., et al. Mesoporous silicon-plga composite microspheres for the double controlled release of biomolecules for orthopedic tissue engineering. Adv Funct Mater 2012, 22:282-293.
38. Godin B., Tasciotti E., Liu X., Serda R.E., Ferrari M. Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem Res 2011, 44:979-989.
39. Martinez J.O., Boada C., Yazdi I.K., Evangelopoulos M., Brown B.S., Liu X., et al. Short and long term, in vitro and in vivo correlations of cellular and tissue responses to mesoporous silicon nanovectors. Small 2013, 9:1722-1733.
40. Tasciotti E., Godin B., Martinez J.O., Chiappini C., Bhavane R., Liu X., et al. Near-infrared imaging method for the in vivo assessment of the biodistribution of nanoporous silicon particles. Mol Imag 2011, 10:56-68.
41. Chiappini C., Tasciotti E., Fakhoury J.R., Fine D., Pullan L., Wang Y.C., et al. Tailored porous silicon microparticles: fabrication and properties. Chem Phys Chem 2010, 11:1029-1035.
42. Kim J., Cho J., Seidler P.M., Kurland N.E., Yadavalli V.K. Investigations of chemical modifications of amino-terminated organic films on silicon substrates and controlled protein immobilization. Langmuir 2010, 26:2599-2608.
43. Park M.H., Choi M.S., Kwak D.H., Oh K.W., Yoon do Y., Han S.B., et al. Anti-cancer effect of bee venom in prostate cancer cells through activation of caspase pathway via inactivation of nf-kappab. Prostate 2011, 71:801-812.
44. Huang H., Held-Feindt J., Buhl R., Mehdorn H.M., Mentlein R. Expression of vegf and its receptors in different brain tumors. Neurol Res 2005, 27:371-377.
45. Xia G., Kumar S.R., Hawes D., Cai J., Hassanieh L., Groshen S., et al. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol 2006, 175:1245-1252.
46. Wicki A., Rochlitz C., Orleth A., Ritschard R., Albrecht I., Herrmann R., et al. Targeting tumor-associated endothelial cells: anti-vegfr2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth. Clin Cancer Res 2012, 18:454-464.
47. Ferrati S., Mack A., Chiappini C., Liu X., Bean A.J., Ferrari M., et al. Intracellular trafficking of silicon particles and logic-embedded vectors. Nanoscale 2010, 2:1512-1520.
48. Godin B., Chiappini C., Srinivasan S., Alexander J.F., Yokoi K., Ferrari M., et al. Discoidal porous silicon particles: fabrication and biodistribution in breast cancer bearing mice. Adv Funct Mater 2012, 22:4225-4235.
49. Lyshchik A., Fleischer A.C., Huamani J., Hallahan D.E., Brissova M., Gore J.C. Molecular imaging of vascular endothelial growth factor receptor 2 expression using targeted contrast-enhanced high-frequency ultrasonography. J Ultrasound Med 2007, 26:1575-1586.
50. Rakhmilevich A.L., Hooper A.T., Hicklin D.J., Sondel P.M. Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody. Mol Cancer Ther 2004, 3:969-976.
51. Martinez J.O., Evangelopoulos M., Chiappini C., Liu X., Ferrari M., Tasciotti E. Degradation and biocompatibility of multistage nanovectors in physiological systems. J Biomed Mater Res Part A 2014, 102(10):3540-3549.
52. Martinez J.O., Parodi A., Liu X., Kolonin M.G., Ferrari M., Tasciotti E. Evaluation of cell function upon nanovector internalization. Small 2013, 9:1696-1702.
53. Paudyal B., Paudyal P., Oriuchi N., Hanaoka H., Tominaga H., Endo K. Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64cu-labeled bevacizumab in colorectal cancer xenografts. Cancer Sci 2011, 102:117-121.
54. Blanco E., Sangai T., Hsiao A., Ferrati S., Bai L., Liu X., et al. Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment. Cancer Lett 2013, 334:245-252.
55. Shen H., Rodriguez-Aguayo C., Xu R., Gonzalez-Villasana V., Mai J., Huang Y., et al. Enhancing chemotherapy response with sustained epha2 silencing using multistage vector delivery. Clin Cancer Res 2013, 19:1806-1815.
56. Shen H., You J., Zhang G., Ziemys A., Li Q., Bai L., et al. Cooperative, nanoparticle-enabled thermal therapy of breast cancer. Adv Healthc Mater 2012, 1:84-89.
57. Shen J., Xu R., Mai J., Kim H.C., Guo X., Qin G., et al. High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics. ACS Nano 2013, 7:9867-9880.